The FIGHT DMD Trial

The FIGHT DMD Trial The FIGHT DMD trial is a phase 2 randomized, placebo-controlled study evaluating an oral medication c You can read more about these studies here.

Fibrosis is the process of replacing normal tissue with scarred tissue which cannot function like normal tissue. Scarring of the heart is part of the disease process in Duchenne. Ifetroban is being studied as a potential anti-fibrotic medication in several diseases but is not approved for and has never been studied in DMD patients. Studies in animal models of DMD showed oral ifetroban can prevent the scarring in the heart associated with Duchenne and improve survival compared to placebo.

Lovely time sharing our FIGHT DMD Trial’s progress at the Parent Project Muscular Dystropy meeting. FightDMDtrial.com
07/04/2023

Lovely time sharing our FIGHT DMD Trial’s progress at the Parent Project Muscular Dystropy meeting. FightDMDtrial.com

Early-stage cohort completed enrollment! Late-stage cohort still enrolling! Please consider participating if you have an...
08/12/2022

Early-stage cohort completed enrollment! Late-stage cohort still enrolling! Please consider participating if you have an LVEF between 35-45%!

Researchers at Cumberland Pharmaceuticals Inc. are seeking boys and men living with Duchenne muscular dystrophy (DMD) to participate in a phase 2 clinical trial to evaluate the safety, and efficacy of oral ifetroban to treat the heart disease associated with DMD.

Address

Nashville, TN

Website

Alerts

Be the first to know and let us send you an email when The FIGHT DMD Trial posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category